Table of contents
- Trial overview
- Who can participate
- What is being measured
- Study design and treatment groups
- Why this trial matters
Trial overview
The available trial data describe one interventional study of Vafidemstat in schizophrenia.[1] The study is titled the EVOLUTION study and is designed to evaluate the efficacy of Vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia.[1]
This trial is in Phase 2 and has a status of Authorised.[1] The planned enrollment is 239 participants.[1]
Who can participate
The study targets adult patients with schizophrenia.[1] The trial summary says it is meant to assess the effect of Vafidemstat on negative symptoms of schizophrenia in adult patients.[1]
The source data do not provide more detailed entry rules, such as age limits beyond adulthood, symptom severity thresholds, or other medical requirements.[1]
What is being measured
The main outcome is the change in the PANSS Factor Score for Negative Symptoms from baseline to week 24.[1] PANSS is a symptom rating scale used in schizophrenia research, and this part of the score focuses on negative symptoms such as low motivation, less speech, and reduced emotional expression.[1]
“Baseline” means the starting point before treatment effects are measured, and “week 24” means 24 weeks after the study begins.[1] This tells researchers whether the treatment group changes more than the placebo group over time.[1]
Study design and treatment groups
The trial compares Vafidemstat with placebo, which is a look-alike capsule that contains no drug substance.[1] The placebo capsules are described as Swedish orange colored size 3 capsules that look identical to the Vafidemstat capsules.[1]
The intervention is given by oral use, meaning it is taken by mouth.[1] The study is therefore designed to test whether the active treatment leads to better symptom improvement than placebo in a fair comparison.[1]
Why this trial matters
Schizophrenia can include symptoms that are difficult to treat, especially negative symptoms and thinking problems.[1] This trial is important because it focuses on those harder-to-treat areas rather than only on general symptom control.[1]
Because the study is in Phase 2, it is part of the early testing stage that helps show whether a treatment may be useful for larger future studies.[1] The results will help researchers understand if Vafidemstat deserves further study for schizophrenia.[1]
